Abstract: This application relates to a newly identified animal cell structure, the midbody scar. This structure is a remnant of the midbody that is retained by one daughter cell following cytokinesis and persists through multiple subsequent cell cycles. The midbody scar can be useful as a marker of dividing cells or of a cell's replicative age.
Abstract: Disclosed are high throughput assay systems and methods for identifying agents that alter the level of expression of proteins in mammalian cells, particularly integral membrane proteins.
Type:
Grant
Filed:
July 8, 2008
Date of Patent:
March 16, 2010
Assignee:
ChanTest, Inc.
Inventors:
Arthur M. Brown, Eckhard Ficker, Barbara A. Wible
Abstract: The invention provides for a process for preparing a sensitivity control for blood group determination including dissolving an amount of an antigen in water to give an antigen solution of known concentration, contacting the antigen solution with cells to allow insertion of antigen molecules into the cell membranes of the cells to give transformed cells or contacting the antigen solution with cells that have been modified by the insertion of a linker molecule into the membranes of the cells to allow attachment of antigen molecules to the linker molecules to give transformed cells, washing the transformed cells to give a transformed cell solution, and determining the concentration of the transformed cell solution to enable the solution to be used as a sensitivity control for blood group determination.
Type:
Grant
Filed:
October 16, 2002
Date of Patent:
March 16, 2010
Assignee:
KIWI Ingenuity Limited
Inventors:
Deborah Adella Blake, Lissa Gwyneth Gilliver, Stephen Michael Henry, Ji Chen
Abstract: Methods for differentially identifying cells in an instrument employ compositions containing a combination of selected antibodies and fluorescent dyes having different cellular distribution patterns and specificities, as well as antibodies and fluorescent dyes characterized by overlapping emission spectra which form non-compensatable spectral patterns. When utilizing the compositions described herein consisting of fluorescent dyes and fluorochrome labeled antibodies with overlapping spectra that cannot be separated or distinguished based upon optical or electronic compensation means, a new fluorescent footprint is established. This new fluorescent footprint is a result of the overlapping spectra and the combined cellular staining patterns of the dyes and fluorochrome labeled antibodies chosen for the composition. The new fluorescent footprint results in histogram patterns that are useful for the identification of additional cell populations or subtypes in hematological disease.
Type:
Grant
Filed:
June 27, 2006
Date of Patent:
March 9, 2010
Assignee:
Beckman Coulter, Inc.
Inventors:
Ronald D. Paul, Oilda Rubio, Diana B. Careaga, Lidice L. Lopez, Ravindra Mylvaganam
Abstract: The present invention relates generally to assays, methods, and kits that provide reagent mixes and instructions for determining the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells.
Abstract: Methods and compositions comprising immunoassays for the detection of antigens and antibodies in a sample are described. In particular, the present invention provides assays that are useful for the rapid and simultaneous detection of multiple different antigens and antibodies. In preferred embodiments, the assays include fluorescent labels of multiple wavelengths or intensities, which are used to label the antigens and antibodies directly and to label beads coated with molecules specific for the antigen or antibody. The detection of a fluorescence shift indicates the presence or identity of the antigen or antibody in the sample.
Type:
Grant
Filed:
September 27, 2002
Date of Patent:
February 9, 2010
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: An assay technique for label-free, highly parallel, qualitative and quantitative detection of specific cell populations in a sample and for assessing cell functional status, cell-cell interactions and cellular responses to drugs, environmental toxins, bacteria, viruses and other factors that may affect cell function.
Type:
Grant
Filed:
June 16, 2006
Date of Patent:
February 2, 2010
Assignee:
Ciencia, Inc.
Inventors:
Michael A. Lynes, Salvador M. Fernández
Abstract: The present invention in one embodiment is an early detection marker for chronic or acute inflammatory-associated diseases. Chronic diseases may include atherosclerosis, Alzheimer's disease, asthma, rheumatoid arthritis, osteoarthritis, and inflammatory diseases of the bowel such as Crohn's disease, Ulcerative colitis, Irritable bowel syndrome and Inflammatory bowel disease. Acute diseases may include sepsis, acute systemic infections, acute lung injury, and acute respiratory distress syndrome.
Type:
Grant
Filed:
February 28, 2007
Date of Patent:
February 2, 2010
Assignee:
The Board of Regents of the University of Oklahoma
Abstract: Methods and compositions for the detection and diagnosis of infectious diseases are provided. In particular, efficient and sensitive methods and compositions for the detection of active mycobacterial disease are provided for distinguishing between individuals having active disease, and individuals who have been immunologically exposed, such as those infected with a mycobacterium but are without active disease, or those who have been vaccinated with BCG. The methods comprise topical application of antigen compositions for transdermal delivery.
Abstract: Methods for operating a sensor device are provided, which may include (a) providing at a site (e.g., implanting in a patient) a device which comprises at least first and second reservoirs, a first sensor and corresponding first reference sensor located within the first reservoir, a second sensor and corresponding second reference sensor located within the second reservoir, a first reservoir cap closing an opening in the first reservoir and a second reservoir cap closing an opening in the second reservoir, and a power source, control circuitry, and electrodes for selectively disintegrating each reservoir cap; (b) disintegrating the first reservoir cap and operating the first sensor and reference sensor; and (c) using the first reference sensor to determine whether the first sensor is operating properly. If not operating properly, then the control circuitry initiates disintegration of the second reservoir cap and operation of the second sensor and reference sensor.
Type:
Grant
Filed:
October 29, 2007
Date of Patent:
January 19, 2010
Assignee:
MicroCHIPS, Inc.
Inventors:
John T. Santini, Jr., Norman F. Sheppard, Jr., Robert S. Langer, Chung Chang Young
Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.
Type:
Grant
Filed:
September 26, 2006
Date of Patent:
January 19, 2010
Assignee:
DRG International, Inc.
Inventors:
Hasan Kulaksiz, Cyril E Geacintov, Alfred Janetzko, Wolfgang Stremmel
Abstract: Methods and compositions for identifying and treating obesity and obesity-induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject and comparing the measured level to lipocalin-2 to a reference level. Another aspect provides methods of treating insulin resistance, type 2 diabetes and other related complications by administering to a patient a composition that can reduce the circulating levels of lipocalin-2, for example a lipocalin-2 antagonist.
Abstract: A method for detection and/or quantification of cardiac troponin I (cTnI) in a sample derived from an individual's blood, the method being based on a sandwich immunoassay employing at least two capture antibodies and at least one tracer antibody, in which a first capture antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to the part of the cTnI midfragment, which is slightly affected by the interfering factor, and a second capture antibody is directed to another of these parts, and a tracer antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to TnC, which is complexed with cTnI.
Abstract: The invention relates to a reagent and a process for the identification and counting of biological cells in a sample. This reagent comprises a cell lysing agent selected from at least one detergent in a concentration capable of specifically lysing a given type of cells in the sample, and a stain capable of marking the intracellular nucleic acids of the remaining unlysed cells. Application in particular for the identification and counting of cells using an automated analysis system based on flow cytometry.
Type:
Grant
Filed:
December 29, 2006
Date of Patent:
December 29, 2009
Assignee:
ABX
Inventors:
Didier Lefevre, Sylvie Veriac, Henri Champseix
Abstract: A method of separating a cell-containing sample into a substantially cell-depleted portion, and a cell-containing portion comprising at least one of a stem cell, a lymphocyte, and a leukocyte comprises a step in which the sample is received in a vessel with at least one flexible wall. In another step, an additive and particles are added to the sample, wherein the additive substantially binds to the at least one of the stem cell, lymphocyte, and leukocyte, and the particles and wherein the particles substantially bind to the at least one of the stem cell, lymphocyte, and leukocyte, and the additive, thereby producing a cell-containing network. In a further step, the network is separated from the substantially cell-depleted portion by applying a magnetic force.
Type:
Grant
Filed:
January 22, 2004
Date of Patent:
December 8, 2009
Assignee:
Qualigen, Inc
Inventors:
James Wyatt, Matthew Scott, Vijay Mahant
Abstract: Surfaces coated with a target-induced fluorescent compound are used to detect target elements, especially trace elements. The target-induced fluorescent compound does not fluoresce when excited at a specific wavelength until it has bound a target element. The use of these coated surfaces provides several benefits including reduced background for greater sensitivity and eliminating the need to separate target-induced fluorescent compound that has not bound target element from target-induced fluorescent compound that has bound target element. Coated nanoparticles are especially useful for detection of target elements.
Abstract: The invention relates to a photochemical process for the preparation of an activated polymer surface having an active fluoro group using 1-fluoro-2-nitro-4-azidobenzene to form the activated polymer surface and then immobilizing a biomolecule thereon by forming a covalent bond between the activated polymer surface and the biomolecule.
Type:
Grant
Filed:
June 10, 2002
Date of Patent:
December 8, 2009
Assignee:
Council of Industrial and Scientific Research
Abstract: A method useful for the enumeration of cell populations in a biological sample includes the steps of reacting in a single reaction mixture a sample, a first antibody labeled with a fluorochrome having a first emission spectrum and an additional antibody. The first antibody binds to an antigenic determinant differentially expressed on leukocytes and non-leukocytes. The additional antibody binds to an antigenic determinant differentially expressed on mature and immature granulocytes or myeloid cells, and is labeled either with the first fluorochrome or an additional fluorochrome having an emission spectrum distinguishable from the first emission spectrum. The reaction mixture can be mixed with a nucleic acid dye having an emission spectrum that overlaps with one of the first or additional emission spectra. The reaction mixture may be treated with a lytic system that differentially lyses non-nucleated red blood cells and conserves leukocytes.
Type:
Grant
Filed:
May 17, 2005
Date of Patent:
December 1, 2009
Assignee:
Beckman Coulter, Inc.
Inventors:
Ronald D. Paul, James L. Wyatt, Barbara Carrillo, Oilda Rubio, Diana B. Careaga, Lidice L. Lopez
Abstract: The present invention provides a method for detecting autoantibodies in a subject which reacts with a GP73 antigen. Increased levels of GP73-specific autoantibodies in a sample from the subject which bind to GP73 antigen are indicative of liver disease in the subject.